Ghana's Administrator of the Ghana Medical Trust Fund, Adjoa Obuobia Darko-Opoku, led a team to Atlantic Lifesciences Limited to explore a partnership to manufacture life-saving medicines locally. This move could significantly reduce the cost of treatment for thousands of Ghanaians.
Ghana Takes Step to Make Life-Saving Medicines Affordable
The Ghana Medical Trust Fund is exploring a strategic partnership with Atlantic Lifesciences Limited and the PharmaNova Group to locally manufacture critical medicines for cancer, cardiovascular diseases, and other chronic conditions. This move aligns with the government's broader vision of strengthening Ghana's pharmaceutical manufacturing capacity and building a more resilient and self-sufficient healthcare system.
The partnership aims to reduce Ghana's dependence on costly imports and make life-saving medicines more affordable for patients. Administrator Adjoa Obuobia Darko-Opoku said discussions between the two sides would continue, with particular attention to affordable access to medicines, local pharmaceutical production, and other sustainable interventions capable of lowering the cost of specialised healthcare.
Addressing Chronic Diseases in Ghana
Ghana Medical Trust Fund Administrator Adjoa Obuobia Darko-Opoku said the proposed collaboration reflects a broader strategy by the Trust Fund to forge partnerships with pharmaceutical companies, healthcare providers, and other organisations capable of bringing expertise, resources, and innovative solutions to the fight against chronic diseases. The Trust Fund believes that by strengthening local pharmaceutical production and securing medicines at competitive prices, it can support more patients while contributing to the development of a stronger and more affordable healthcare system for Ghana.
According to a statement copied to the Ghana News Agency, one of the solutions being explored is the local manufacture of a wide range of cardiovascular medicines, anti-cancer medications, and immuno suppressants to support the next phase of the GMTF services package. This move could significantly reduce the cost of treatment for thousands of Ghanaians.
Ghana's Pharmaceutical Manufacturing Capacity
The initiative also aims to reduce import-related costs, improve the availability of essential drugs, and enable the Fund to use its resources to support a greater number of patients battling chronic and life-threatening diseases. CEO of PharmaNova Ltd., Dhanankay Tripathi, stressed the importance of identifying gaps within Ghana's healthcare system and developing practical solutions that directly respond to the needs of patients.
Atlantic Lifesciences, working with the PharmaNova Group, positions itself as a health solutions provider that identifies critical gaps in healthcare delivery and develops interventions to address them. The visit therefore provided the GMTF team with an opportunity to gain first-hand insight into the company's operations, manufacturing capabilities, and potential contribution to the Trust Fund's work.
What's Next for the Partnership
The proposed collaboration reflects a broader strategy by the Ghana Medical Trust Fund to forge partnerships with pharmaceutical companies, healthcare providers, and other organisations capable of bringing expertise, resources, and innovative solutions to the fight against chronic diseases. Administrator Adjoa Obuobia Darko-Opoku said discussions between the two sides would continue, with particular attention to affordable access to medicines, local pharmaceutical production, and other sustainable interventions capable of lowering the cost of specialised healthcare.
This move could have far-reaching implications for Ghana's healthcare system, enabling the Trust Fund to support more patients while contributing to the development of a stronger and more affordable healthcare system for Ghana. As the partnership moves forward, it will be crucial to monitor its progress and assess its impact on the lives of Ghanaians.
Source: Joy Online
